← Back to Search

Dopamine for Pulmonary Diffusion and Capillary Blood Volume during Exercise. However, since the Layman Condition List is "Health" which is very broad, it is difficult to specify a specific condition for this trial

N/A

Waitlist Available

Led By Michael K Stickland, PhD

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No known cardiac or pulmonary disease

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up dopamine (day 1), metoclopramide (day 2), placebos (day 3) *order randomized

Awards & highlights

Study Summary

This trial looks at the effects of dopamine on blood vessels and exercise performance.

Who is the study for?

This trial is for healthy, physically active individuals with a BMI under 30 who exercise more than twice a week. It's not suitable for those with known heart or lung diseases, high BMI over 30, on certain medications affecting dopamine pathways, or women who are pregnant.Check my eligibility

What is being tested?

The study investigates how dopamine and blocking its receptors affect blood flow in the lungs and exercise tolerance. Participants will undergo different levels of exercise and receive either dopamine, metoclopramide (blocks dopamine-2 receptors), or placebos.See study design

What are the potential side effects?

Possible side effects may include changes in blood pressure, increased heart rate from dopamine infusion; nausea or restlessness from metoclopramide; fatigue due to exercise; but specific side effect profiles will be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have any known heart or lung diseases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ dopamine (day 1), metoclopramide (day 2), placebos (day 3) *order randomized

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~dopamine (day 1), metoclopramide (day 2), placebos (day 3) *order randomized

This trial's timeline: 3 weeks for screening, Varies for treatment, and dopamine (day 1), metoclopramide (day 2), placebos (day 3) *order randomized for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cardiac Output

Change in Pulmonary Capillary Blood Volume

Diffusing Capacity for Carbon Monoxide

+2 more

Secondary outcome measures

Exercise Tolerance

Exertional Dyspnea

Trial Design

3Treatment groups

Experimental Treatment

Group I: PlacebosExperimental Treatment4 Interventions

Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max

Group II: MetoclopramideExperimental Treatment4 Interventions

Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max

Group III: DopamineExperimental Treatment4 Interventions

Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dopamine

2003

Completed Phase 4

~23320

Metoclopramide

2016

Completed Phase 4

~29230

Placebos

2019

Completed Phase 4

~2030

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor

889 Previous Clinical Trials

385,142 Total Patients Enrolled

Natural Sciences and Engineering Research Council, CanadaOTHER

58 Previous Clinical Trials

3,066 Total Patients Enrolled

Michael K Stickland, PhDPrincipal InvestigatorUniversity of Alberta

9 Previous Clinical Trials

4,508 Total Patients Enrolled

Media Library

Exercise - 60% Clinical Trial Eligibility Overview. Trial Name: NCT02965963 — N/A

Health Research Study Groups: Dopamine, Metoclopramide, Placebos

Health Clinical Trial 2023: Exercise - 60% Highlights & Side Effects. Trial Name: NCT02965963 — N/A

Exercise - 60% 2023 Treatment Timeline for Medical Study. Trial Name: NCT02965963 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an opportunity to participate in this clinical trial?

"Prospective participants should be in good health and range between 18 to 50 years of age. A total of 35 enrollees are required for this trial."

Answered by AI

Does the age restriction for this research trial exceed 30 years of age?

"The age range for this clinical trial is between 18 and 50 years. Alternative trials exist to accommodate younger than 18 or older than 65 participants, comprising 6 studies in the former case and 12 in the latter."

Answered by AI

To what condition is Exercise - 60% typically prescribed?

"Exercise - 60% is a common therapy for shock, as well as gastroparesis and flatulence exacerbated by pharmacotherapy."

Answered by AI

Are recruitment efforts still underway for this trial?

"Affirmative. Per the information visible on clinicaltrials.gov, this trial began accepting applicants as of December 1st 2016 and is still searching for suitable candidates as of September 19th 2022. 35 people will be accepted at a single medical centre."

Answered by AI

What is the scale of this experimental endeavor?

"Affirmative. According to the information on clinicaltrials.gov, this medical study is presently recruiting participants and was initially made available on December 1st 2016. The most recent update occurred on September 19th 2022 with a goal of finding 35 patients from one site location."

Answered by AI

Recent research and studies

European Respiratory JournalJournal

Exercise Stress Echocardiography for the Study of the Pulmonary Circulation

Argiento, P., N. Chesler, M. Mule, M. D'Alto, E. Bossone, P. Unger, and R. Naeije. 2009. “Exercise Stress Echocardiography for the Study of the Pulmonary Circulation”. European Respiratory Journal. European Respiratory Society (ERS). doi:10.1183/09031936.00076009.

relative Importance of Diffusion and Chemical Reaction Rates in Determining Rate of Exchange of Gases in the Human Lung, with Special Reference to True Diffusing Capacity of Pulmonary Membrane and Volume of Blood in the Lung CapillariesJournal

<i>relative Importance of Diffusion and Chemical Reaction Rates in Determining Rate of Exchange of Gases in the Human Lung, with Special Reference to True Diffusing Capacity of Pulmonary Membrane and Volume of Blood in the Lung Capillaries</i>

Roughton, F. J. W., and R. E. Forster. 1957. “relative Importance of Diffusion and Chemical Reaction Rates in Determining Rate of Exchange of Gases in the Human Lung, with Special Reference to True Diffusing Capacity of Pulmonary Membrane and Volume of Blood in the Lung Capillaries”. Journal of Applied Physiology. American Physiological Society. doi:10.1152/jappl.1957.11.2.290.

Journal of Applied PhysiologyJournal

The Effects of Dobutamine and Dopamine on Intrapulmonary Shunt and Gas Exchange in Healthy Humans

Bryan, Tracey L., Sean van Diepen, Mohit Bhutani, Miriam Shanks, Robert C. Welsh, and Michael K. Stickland. 2012. “The Effects of Dobutamine and Dopamine on Intrapulmonary Shunt and Gas Exchange in Healthy Humans”. Journal of Applied Physiology. American Physiological Society. doi:10.1152/japplphysiol.00404.2012.

The Journal of PhysiologyJournal